Figure 4.

The ICB treatment response mechanism explained in the scCURE identified changed CD8⁺ T cells between pre-treatment samples and post-treatment Rs

(A) Heterogeneity of the dynamical CD8⁺ T cells shown in the t-SNE scatterplot. Cell cluster frequency shown as a fraction of total cells in pre-treatment and post-treatment.

(B) Heatmap shows the expression of canonical T cell functional markers across cell clusters.

(C) Pseudotime trajectory reconstruction and its association with cell clusters and sample labels.

(D) Heatmap in t-SNE space showing the signature scores for terminally exhausted and progenitor exhausted CD8⁺ T cells.

(E) Terminally exhausted and progenitor exhausted CD8⁺ T cell signatures across CD8⁺ T cell subtypes. Asterisks indicate statistical significance by Kruskal-Wallis test between groups for each signature as follows: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

(F) Enriched GSEA hallmarks of two representative CD8⁺ T clusters of pre- and post-treatment samples (Benjamini-Hochberg [BH]-adjusted p < 0.05).

(G) Signature scores for the top 30 markers of CD8-C5-IL7R in bulk RNA-seq samples from the GEO: GSE91061 melanoma cohort.

(H) Survival analysis using the top 30 markers of CD8-C5-IL7R on TCGA melanoma data.